Cocaine-and Amphetamine Regulated Transcript (CART) peptide is expressed in the brain, endocrine and neuroendocrine systems and secreted into the serum. It is thought to play a role in regulation of hypothalamic pituitary functions. Here we report a spatial and temporal analysis of Cart expression in the pituitaries of adult and developing normal and mutant mice with hypopituitarism. We found that Prop1 is not necessary for initiation of Cart expression in the fetal pituitary at e14.5, but it is required indirectly for maintenance of Cart expression in the postnatal anterior pituitary gland. Pou1f1 deficiency has no effect on Cart expression before or after birth. There is no 1:1 correspondence between CART and any particular cell type. In neonates, CART is detected primarily in non-proliferating, POU1F1-positive cells. CART is also found in some cells that express TSH and GH suggesting a correspondence with committed progenitors of the POU1F1 lineage. In summary, we have characterized the normal temporal and cell specific expression of CART in mouse development and demonstrate that postnatal CART expression in the pituitary gland requires PROP1.
Introduction
CART is expressed in several organs of the neuroendocrine and endocrine system including the pituitary gland, brain, adrenal gland, and the somatostatin producing cells of the pancreatic islets [1] [2] [3] [4] . CART is most abundant in the hypothalamus [5] . In rodents, two different splice variants of the Cart transcript result in the production of two pro-peptides of different lengths, called proCART 1-89 and proCART 1-102. The proCART peptides contain several cleavage sites that allow post-translational processing by prohormone convertases resulting in two biologically active forms: CART 55-102 and CART 62-102. CART 55-102 is the predominant form in the anterior pituitary gland [5] [6] [7] [8] [9] [10] [11] [12] . CART peptides may have a hormonal role as they are found in the pituitary portal blood system and peripheral blood [13] , in addition to the anterior and posterior pituitary lobes [1, 14] .
CART is thought to function in inhibition of food intake, stimulation of energy expenditure, and regulation of the hypothalamic-pituitary axes [15] [16] [17] [18] [19] . In the hypothalamic-pituitary-thyroid (HPT) axis, functional studies in rats and cell lines demonstrate that CART peptide modulates TRH-induced prolactin secretion by influencing the stimulatory affect of TRH [18, [20] [21] [22] . There is also evidence that CART regulates the hypothlamic-pituitary-adrenal (HPA) axis at the level of the hypothalamus, where it is expressed together with corticotropin-releasing hormone (CRH) [23] . In vitro studies have shown that CART stimulates the release of CRH from hypothalamic explants [24] . These studies suggest that CART could regulate pituitary function both directly and indirectly.
Several genes have been identified that are required for pituitary development and function in humans and mice [25] [26] [27] . Among the best known are PROP1 and POU1F1, which encode two pituitary-specific homeobox transcription factors [28] [29] [30] . Mutations in POU1F1 cause Combined Pituitary Hormone Deficiency (CPHD), which is typically characterized by lack of GH, TSH and PRL [30] [31] [32] [33] [34] , while mutations in PROP1 cause progressive hormone deficiency that can include GH, TSH, PRL, gonadotropins and ACTH [29, [35] [36] [37] [38] [39] .
Mice with mutations in Prop1 and Pou1f1 have been invaluable for revealing the genetic hierarchy of regulatory control and for understanding disease pathophysiology. PROP1 is expressed in Rathke's pouch, the rudiment of the anterior and intermediate lobes of the rodent pituitary gland, at e10.5 and it wanes by e14.5 [37] . The expression of Pou1f11 is detectable at e14.5, and expression of Tshb, Gh and Prl are detectable a day later, e15.5 [40, 41] . Ames dwarf mice (Prop1 df/df ) have an abnormally shaped Rathke's pouch and hypoplastic anterior lobe because proliferating progenitor cells are unable to migrate from the niche into the anterior lobe [42] [43] [44] . Prop1 df/df mice also fail to activate Pou1f1, and although the Snell dwarf mice (Pou1f1 dw/dw ) express Prop1, they fail to activate Tshb, Gh and Prl expression [32, 37, 39, 44] . These types of studies, together with lineage tracing experiments, established that Prop1 is expressed in all pituitary progenitors, it binds the Pou1f1 regulatory elements and activates its expression, and subsequently, POU1F1 directly activates the hormone genes that define somatotropes, thyrotropes and lactotropes [37, 45] .
Identification of target genes is an important step in understanding the molecular mechanisms of transcription factor action. Many downstream targets of POU1F1 have been identified [32, 46, 47] , but other than Pou1f1 and Hesx1, few direct targets besides Prop1 are known [37, 48] . We carried out gene expression profiling with RNA from neonatal pituitaries of normal, Prop1 ) were purchased from The Jackson Laboratory as an inbred stock (DW/J) (Bar Harbor, ME). Both strains have been maintained as colonies at the University of Michigan through heterozygous matings. The morning after conception is designated e0.5 and the day of birth is designated as P1. Mice were euthanized using 10 to 30% carbon dioxide inhalation followed by bilateral pneumothorax.
Materials and Methods

Mice
PCR genotyping
The genotypes of Prop1 df/df (p.Ser83Pro) and Pou1f1 dw/dw (p.Trp251Cys) mice [32, 37] were determined as described [38, 50] .
Tissue Preparation and Histology
Embryos were fixed in 4% formaldehyde in PBS at 4°C for different times depending on the age of the embryo. Fixation was 2 hours for e14.5 and e16.5, overnight for P1 and P8, and 30 minutes for adult mouse pituitaries. The tissue was washed with PBS, dehydrated to 70% ethanol and embedded in a Tissue Tek VIP Paraffin tissue processing machine (Miles Scientific). 6 μm thick sagittal sections were prepared from embryos collected at e14.5 and e16.5, and coronal sections were prepared from postnatal pups and adult pituitaries.
Immunohistochemistry
Immunostaining for CART protein was done with the anti-CART (55-102) antibody (1:5000, Phoenix Pharmaceuticals). The specificity of the CART (55-102) antibody has been proven with immunohistochemistry experiments were the CART antisera was preabsorbed with the CART peptide [51] . Immunostaining for pituitary hormone markers was performed using anti-TSH, anti-ACTH, anti-LH, anti-FSH, anti-GH, and anti-PRL antibodies, (1:1000, National Hormone and Peptide Program, UCLA Medical Center, Torrance, CA). For double immunostaining of CART and pituitary hormones, the paraffin sections were hydrated and incubated for 20 minutes in an aqueous solution of 3%H 2 O 2 , 50% methanol to block endogenous peroxidases. All slides were placed in normal goat serum block (5% goat serum, 3% BSA, and 0.5% Tween-20 in PBS) for 10 minutes at room temperature. 100 μl of anti-CART antibody was placed on each slide on a wax ring and incubated over night at 4°C. A 100 μl aliquot of biotinylated anti-rabbit IgG secondary antibody (Jackson Immuno Research, West Grove, PA) was incubated on each slide for 30 minutes, and subsequently CART was detected using the tyramide signal amplification (TSA) and Fluorescein Isothiocynate (FITC) kit (according to protocol, Perkin-Elmer, Boston, MA). After washing slides in 1XPBS-T (phosphate buffered saline with 0.01% Tween-20), slides were boiled in 0.01 M citrate buffer to expose epitopes. Specifically, slides and citrate buffer were placed in the microwave for 5 minutes at 40% power. The slides were cooled for 30 minutes in the same citrate buffer [52] After washing the slides in 1X PBS, an Avidin/Biotin block was done for 15 minutes according to protocol (Vector Labs, Burlingame, CA). All hormone antibodies were diluted in this block and were incubated on the slides over night at 4°C, except for GH which was incubated for 1 hour at room temperature. For double immunostaining with CART and antibodies against the nuclear factors antiKi67 (1:200, Novocastra, Newcastel, United Kingdom), anti-TPIT (1:200, from Dr. Jacques Drouin), anti-NR5A1 (1:100, from Ken-ichirou Morohashi), anti-POU1F1 (1:100, from Simon Rhodes), paraffin sections were boiled in 0.01M citrate for 10 minutes, or 15 minutes for anti-PROP1 antibody (1:100, from Aimee Ryan) [45] . These incubations were followed by a 20 minute incubation in an aqueous solution of 3% H 2 O 2 , 50% methanol, and a normal goat serum block (5% goat serum, 3% BSA, and 0.5% Tween-20 in PBS) for 10 minutes at room temperature. 100 μl of CART antibody was placed on each slide within a wax ring and incubated overnight at 4°C and the secondary and tertiary antibodies as described above were used. 100 μl of the nuclear antibodies were added to the slides and incubated over night at 4°C. We used biotinylated anti-rabbit IgG (Jackson Immuno Research) as a secondary antibody for anti-Ki67, anti-NR5A1, anti-TPIT, and anti-POU1F1, and biotinylated anti-guinea pig IgG (Jackson Immuno Resaerch) secondary antibody for anti-PROP1. Nuclear antibodies were detected using either the tyramide signal amplification (TSA) and fluorescein isothiocynate (FITC) kit (according to protocol, Perkin-Elmer, Boston, MA), or streptavidin-conjugated Alexa-fluor 488 (1:200, S11223, Invitrogen). Cell nuclei were stained with DAPI (1:200) for 5 minutes, washed with 1XPBS, and mounted with aqueous mounting media. See Table 1 .
Pregnant mice were injected IP with 100mg BrdU per gram of body weight 2 hours prior to collecting embryos. After processing, tissue sections were boiled in 0.01M citrate for 10 minutes, followed by 20 minute incubation in an aqueous solution of 3% H 2 O 2 , 50% methanol. The slides were then incubated for 1 hr in a mouse IgG block. BrdU detection was performed as described by [43] with the anti-BrdU antibody (1:100, AbD Serotec). The secondary biotin anti-rat IgG (1:200, 711-066-152, Jackson Immunoresearch, Westgrove, PA) was used followed by detection with Alexa Flour 488. Microwave treatment, Avidin/Biotin Block, and CART immunostaining were all as described above.
All single and double-immunohistochemistry experiments were done with the appropriate negative controls (S1 Fig).
Cells were counted using ImageJ (1.51a) Software (National Institute of Health).
Results
CART is expressed in the developing anterior and posterior pituitary gland
If Cart were a direct target of Prop1, then we would expect Cart expression to be activated in a spatial and temporal manner coincident or overlapping with Prop1 expression in normal mice and absent or reduced in Prop1 df/df mutants. CART was not detected at e12.5 in the pituitary gland when PROP1 is expressed (Fig 1A and 1B) . We detected the CART protein at e14.5 in the developing anterior lobe and infundibulum using immunohistochemistry. This pattern persists at e16.5 and the intensity of staining is increased, but there is no striking difference between the control and the Prop1 df/df mutants at either of these time points (Fig 1C-1F ).
There are fewer cells that stain for CART in the anterior lobe of Prop1 df/df at e16.5, but the anterior lobe is hypoplastic at that time. At P1 the CART immunostaining is increasingly prominent in the posterior lobes of both the normal and Prop1 df/df pituitary glands (Fig 1G and 1H ).
By P8 CART is detected throughout the anterior and posterior lobe in the control pituitary gland, but it is almost completely absent from the anterior lobe of Prop1 df/df mutants (Fig 1I   and 1J ). In contrast, there is no obvious difference between CART expression in control and Pou1f1 dw/dw mutant pituitary glands at P8 (Fig 1K and 1L) . Thus, activation of CART expression is Prop1-independent, but Prop1 is clearly essential for sustaining CART expression in the anterior lobe postnatally. In contrast, Pou1f1 is not essential for either activation or maintenance of Cart expression.
CART expression predominates in somatotropes of the postnatal pituitary gland
We determined the cell specific expression of CART in the pituitary gland at P8 using immunohistochemistry to co-stain for CART and each of the pituitary hormones individually. TSHβwas expressed in 16 to 21% of the CART positive cells in the pituitary gland at P8 (n = 3, Fig 2A, yellow arrow) . This is a large portion of the TSHβpopulation as 62 to 79% (n = 3) of the TSHβcells were CART positive. More than half of the CART expressing cells were also positive for GH (57 to 68%, n = 3). (Fig 2B, yellow arrow ). There were many GH only cells (31 to 40%, n = 3, red arrow) and CART only cells (green arrow). We did not detect any co-localization of CART with ACTH, LHβ, FSHβ, or PRL at P8 (Fig 2C-2F) . The Pou1f1 dw/dw and Prop1 df/df mutant pituitaries are nearly devoid of GH, TSHβ, and PRL [41, 44] . It is intriguing that despite identical deficits in Pou1f1 lineage determination, CART protein expression is normal in Pou1f1 dw/dw but not detectable in Prop1 df/df mutants (Fig 1) . To determine whether any of the CART positive cells in the Pou1f1 dw/dw mutant were producing hormones, we carried co-staining with CART the antibody and an "all hormone" immunostain, by combining antibodies specific for TSHβ, GH, ACTH, LHβ, FSHβ, and PRL and using a common tertiary streptavidin-Cy3 antibody. In the control, 59 to 65% (n = 3) of the CART positive cells co-localized with a hormone producing cell (yellow arrow) (Fig 2G) , but all of the CART positive cells were hormone negative in the Pou1f1 dw/dw pituitaries ( Fig   2H) . The nature of the CART positive, hormone negative cells is unknown, but the cell morphology resembles that of hormone producing cells. PROP1 is detectable in progenitors that reside in the marginal zone of the anterior lobe and in scattered cells in the parenchyma of the anterior lobe [53] . Lineage tracing experiments show that all hormone-producing cells of the anterior pituitary gland pass through a Prop1   Fig 2. CART expression the pituitary hormones. Co-localization of CART with specific pituitary hormones was determined with a CART-specific antibody (green) and hormone specific antibodies (red) in sections from pituitary glands collected at P8. The hormone specific antibodies were TSHb (A), GH (B), ACTH (C), FSHb (D), LHb (E), and PRL (F). Co-localization is indicated with yellow arrows (A, B). In one CART immunostaining experiment all hormone antibodies were applied together and detected with the same fluorophore (G, H). A few CART positive cells do not express a detectable level of hormone (green arrow) in the Pou1f1 +/+ pituitary (G), but almost all CART positive cells do not co-localize with any hormones in the somatotrope deficient Pou1f1 dw/dw anterior pituitary (H). The CART protein (red) does not co-localize with PROP1 (green) in the developing pituitary gland at e14.5 (I). Images A-I were taken at 400X and scale bar is 100 μm. doi:10.1371/journal.pone.0160068.g002 expressing progenitor [45] . At e14.5, PROP1 immunostaining is detectable in cells of the most caudal end of the marginal zone and the developing anterior lobe, but expression does not overlap with CART at this time (Fig 2I) . This suggests that CART expression may be associated with a progenitor that has initiated commitment to hormone production, but has accumulated low levels of hormone, if any.
CART co-localizes with multiple cell specific transcription factors, but primarily with POU1F1 Some lineage specific transcription factors are detectable prior to the hormone. For example, Pou1f1 [54] and Nr5a1 [55, 56] expression precede the detection of GH and LH respectively [38, 57] . To test whether CART is expressed in committed progenitors, we carried out additional co-immunostaining experiments. At P8 the majority of PROP1 immunostaining is detected in the cytoplasm of cells that have migrated away from the marginal zone, and there is little or no co-localization with CART (data not shown). At P8 CART does co-localize with a large portion of the POU1F1 positive cells in the control pituitary gland (74 to 82%, n = 3, Fig  3A) , which supports the idea of a CART expressing progenitor. The CART immunostaining is similar in wild type and Pou1f1 dw/dw mutant pituitaries, despite the fact that POU1F1 is not functional and not detectable in the mutants (Fig 3B) . TPIT (TBX19) is a positive regulator for late POMC cell differentiation and POMC expression, although it is not required for lineage commitment [58, 59] . POMC is processed to produce ACTH in the anterior lobe. We did not detect any co-localization of CART with ACTH at P8 (Fig 2) , but we did detect a few TPIT and CART double positive cells in both the control and Pou1f1 dw/dw pituitary glands (Fig 3C and   3D , yellow arrows). The transcription factor NR5A1 (SF1) is specific to the gonadotropes of the pituitary gland [60] . Although we did not see any co-localization of LHβ or FSHβ with CART, we detected a few CART and NR5A1 positive cells in the control pituitaries (12 to 13% of CART cells, n = 3). We saw slightly more CART and NR5A1 co-localized cells in Pou1f1 dw/dw mutants (41 to 47% of CART cells, n = 3) compared to the control pituitaries (Fig 3E and 3F , yellow arrow), which may be due to the increased number of cells committed to the gonadotrope fate in these mutants [61] . Taken together these results support the idea that CART is expressed in some committed progenitors that have not yet accumulated hormones. Maintenance of CART expression is indirectly dependent upon Prop1 and independent of Pou1f1, placing it between these two transcription factors in a transcriptional hierarchy.
CART is expressed primarily in non-proliferating cells of the postnatal pituitary gland
We hypothesized that the CART expressing cells that have no detectable hormone expression could be committed progenitors that are still in a proliferative state. To test this idea we carried out co-immunostaining with antibodies specific for Ki67 and CART at P8. Ki67 marks all active phases of the cell cycle (G 1 , S, G 2 , and M), but it is absent from resting cells (G 0 ). Only a small fraction of the CART positive cells were also positive for Ki67 in both the control (8 to 15%, n = 3) and Pou1f1 dw/dw (12 to 15%, n = 3) pituitary gland (white arrow) (Fig 4A and 4B) .
We also carried out bromodeoxyuridine (BrdU) labeling at P8 to identify cells in S phase of the cell cycle. Only a small portion of the CART expressing cells also immunostained with BrdU in the control (10-11%, n = 3) and Pou1f1 dw/dw (9 to 13%, n = 3) (Fig 4C and 4D , white arrow),
confirming that the majority of CART expressing cells are non-proliferative. T he few CART expressing cells that are proliferating cells may be among the subset of proliferating, hormone negative, POU1F1 positive cells in the P8 pituitary gland [62] .
Many of the CART cells co-localize with TSHβ (yellow arrow) in the adult pituitary (67-76%, n = 3), but CART only (green arrow) and TSHβ only (red arrow) cells are detectable (Fig 5C) . We did not observe any co-localization of CART with LHβ, FSHβ, or ACTH in the adult pituitary (Fig 5D-5F ).
Discussion
Cart expression is dependent on Prop1 after birth, but not embryonically
We identified Cart in a screen for genes whose postnatal expression was specifically dependent upon Prop1 but not Pou1f1 [49] . Here we report that the initiation and embryonic stages of Cart expression are independent of Prop1, and the spatial and temporal pattern of Prop1 and Cart expression are inconsistent with Cart being a direct target of Prop1-mediated transactivation during pituitary embryogenesis. Prop1 expression is transient in the fetus, diminishing to very low levels by e14.5, but expression is reactivated briefly after birth during a period of rapid pituitary growth and cell proliferation [37, 48, 53] . The postnatal expression of Cart is Prop1 dependent, and we expect that it is indirect because they are not expressed in the same cells and Pou1f1 dw/dw mice at P8. Co-localization is indicated by white arrows, and CART immunofluorescence in Ki67 or BrdU negative cells is indicated with arrow heads. There are many CART cells in both pituitary genotypes that do not co-localize with any proliferating cells (arrow heads). All images were taken at 400X, and scale bar is 100 μm. doi:10.1371/journal.pone.0160068.g004
embryonically. We expect that the failure to maintain Cart expression after birth in Prop1 df/df , but not Pou1f1 dw/dw mutant mice, is due to the arrest in progenitor development at different stages in these two mutants. Cart expression may mark cells that have transitioned out of Prop1 expression and begun commitment to produce hormones, but do not require Pou1f1 function to maintain Cart expression. It is possible that initial activation of Cart expression involves some of the early acting transcription factors like Pitx2, Lhx3, or Lhx4, [63] [64] [65] and that other Prop1 dependent transcription factors are necessary to maintain its expression postnatally. Candidates for regulating postnatal expression could include Otx1, Notch, Math3, Zfhx3, and Zeb1 [66] [67] [68] [69] [70] .
Cart expression predominates in the POU1F1 lineage but is not uniquely cell-type specific
Cart expression is dynamic and not uniquely cell type specific. Cart is first detected at e14.5 in the developing pituitary gland and then persists through adulthood. It does not exhibit exclusive cell specificity at any stage that we examined. We found predominant co-localization in cells expressing Pou1f1 and GH in neonates, but less co-localization in adult pituitaries. A few cells were detected that express CART and other lineage specific transcription factors like NR5A1 and TPIT, but no co-localization was detected with LH, ACTH or PRL. This developmental shift in co-localization is consistent with the idea that Cart marks a Prop1 dependent progenitor that can give rise to all major hormone producing cell types of the pituitary gland [45] . After Prop1 activation, mutually antagonistic interactions between POU1F1, NR5A1, GATA2, and probably TPIT (TBX19) may ultimately drive cell specification to different lineages [58, 61] . If this is the case, it could explain why Cart expression is detected in a variety of hormone negative committed cells and ultimately becomes more enriched in somatotropes and thyrotropes. It is important to acknowledge that the lack of 1:1 correspondence with CART expression and any particular hormone producing cell type is not unique. The transcriptomes of gonadotropes vary, for example [71] .
Given the dynamic Cart expression we observed in mice, it is perhaps not surprising that the expression and function reported for CART in the rat anterior pituitary is controversial and differs from the mouse. We did not observe Cart expression in mouse lactotropes. However, it was detected in the majority of adult rat lactotropes, expression and secretion of CART 62-102 increased in lactating animals, and CART inhibits TRH-induced prolactin release [20, 21] . Cart expression is repressed by thyroid hormone; levels increase in hypothyroid animals and decrease in hyperthyroid animals [20] . Although another group concurs that CART suppresses prolactin release, they detected CART co-localization only with gonadotropes using an antibody specific to CART 55-102, which is the same antibody that we used [22] . Finally, Cart transcripts reportedly to co-localize with ACTH cells in the rat, and CART secretion is regulated by CRH and glucocorticoids [72] . There may be species differences in CART expression and function, but the basis for the conflicting co-localization studies in the rat are unclear.
In conclusion, we demonstrate that PROP1 is necessary for maintenance, but not initiation, of CART expression in the pituitary gland. The postnatal maintenance of CART expression by PROP1 is likely indirect. We also show CART co-localization with somatotropes in the mouse pituitary gland, along with non-hormone producing cells that could be progenitors. CART expression could be a useful tool for sorting cells in an intermediate differentiation state. 
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